Advanced Nanotechnology-Based Drug Delivery Carriers for Precision Oncology

Nanomedicine is rapidly transforming the landscape of cancer treatment through the development of advanced drug-delivery carriers. Despite notable progress in conventional chemotherapies, major obstacles such as systemic toxicity, suboptimal bioavailability, and the emergence of drug resistance continue to limit patient outcomes. Recent research has intensified efforts to engineer innovative delivery platforms that can offer enhanced specificity, minimize adverse effects, and increase therapeutic efficacy. While lipid-based, polymeric, and inorganic nanoparticles are among the most promising candidates, critical gaps remain in optimizing these carriers for clinical translation. Ongoing debates focus on the reproducibility of nanocarrier synthesis, the correlation between nano-architecture and biological performance, and the dynamic tumor microenvironment’s influence on drug delivery.This Research Topic aims to catalyze advancements in the rational design, functionalization, and implementation of next-generation nanomedicine carriers for cancer therapy. Contributions are sought that address the fundamental mechanisms by which smart nanocarriers—capable of responding to internal stimuli (such as pH changes or enzymatic activity) or external triggers (such as temperature or magnetic fields)—enable controlled, site-specific release of anti-cancer agents. The goal is to bridge experimental and clinical evidence, fostering multidisciplinary dialogue that unpacks how particle size, surface characteristics, and immune system interactions influence the overall efficacy of drug delivery systems. Key questions include identifying optimal engineering strategies for tailored carriers, elucidating pharmacokinetic behavior in complex biological environments, and advancing imaging-guided interventions for solid tumors.The scope of this Research Topic is centered on the development, characterization, and application of innovative nanocarrier platforms uniquely engineered for oncology, with special emphasis on stimuli-responsive designs and translational potential. Beyond foundational research, the topic is open to integrated approaches combining chemistry, materials science, pharmacology, and clinical oncology. To gather further insights into the rapidly evolving field of nano-enabled drug delivery for cancer, we welcome articles addressing, but not limited to, the following themes:- Novel synthesis and design strategies for targeted drug delivery- Pharmacological evaluation of anti-cancer agents in nanoformulations- Interactions between nanocarriers and the immune system in cancer therapy- Imaging and diagnostics integrated with therapeutic delivery- The impact of particle size and surface modifications on tumor targeting- Strategies to overcome drug resistance and improve therapeutic outcomesBy bringing together leading experts, this Research Topic seeks to provide an academic venue where researchers can share forward-thinking insights to improve diagnosis, therapeutics, and patient management strategies.Topic Editor Jonghoon Choi is the founder and CEO of the Feynman Institute of Technology at the Nanomedicine Corp. The other Topic Editors declare no competing interests with regard to the Research Topic subject. Topic editors: Jonghoon Choi, Sylvain Broussy Source: https://www.frontiersin.org/research-topics/78290/advanced-nanotechnology-based-drug-delivery-carriers-for-precision-oncology